Synapsin Pharmaceuticals Inc is categorized under Medical Research in Mount Pleasant, SC and active since 2007.
Synapsin Pharmaceuticals Inc was established in 2007, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Mark S Kindy Phd at the company’s single location by writing to 3384 Shagbark Circle, Mount Pleasant, South Carolina SC 29466 or by phoning (843) 670-4504. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Synapsin Pharmaceuticals Inc |
| Contact Person: | Mark S Kindy Phd |
| Address: | 3384 Shagbark Circle, Mount Pleasant, South Carolina 29466 |
| Phone Number: | (843) 670-4504 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Synapsin Pharmaceuticals Inc was started in 2007 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Mark S Kindy Phd for inquiries that concern Synapsin Pharmaceuticals Inc by calling the company number (843) 670-4504, as your correspondence is most welcome. Additionally, the physical location of the single location of Synapsin Pharmaceuticals Inc can be found at the coordinates 32.909911,-79.796783 as well as the street address 3384 Shagbark Circle in Mount Pleasant, South Carolina 29466.
For its online presence, you may visit Synapsin Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.